Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
JD HEALTH
06618
5
ALI HEALTH
00241
| (FY)Aug 31, 2025 | (Q4)Aug 31, 2025 | (Q3)May 31, 2025 | (Q2)Feb 28, 2025 | (Q1)Nov 30, 2024 | (FY)Aug 31, 2024 | (Q4)Aug 31, 2024 | (Q3)May 31, 2024 | (Q2)Feb 29, 2024 | (Q1)Nov 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 14.49%-2.61M | -62.24%-1.01M | 60.09%-340.2K | 31.11%-70.77K | 19.49%-1.19M | 9.95%-3.06M | 35.33%-625.1K | -37.67%-852.48K | 90.78%-102.72K | -112.63%-1.48M |
| Net income from continuing operations | -76.40%367.57K | 61.31%-1.15M | -123.25%-737.04K | -809.17%-2.43M | 360.47%4.69M | 130.39%1.56M | 37.91%-2.97M | 3,517.64%3.17M | -45.51%343.17K | 196.80%1.02M |
| Operating gains losses | -166.36%-1.62M | 41.08%-228.33K | -404.41%-877.32K | -279.59%-310.56K | -665.04%-202.03K | -115.85%-607.55K | -114.62%-387.56K | -150.92%-173.93K | -112.03%-81.81K | -77.81%35.76K |
| Depreciation and amortization | -35.20%184.49K | -33.48%46.12K | -33.48%46.12K | -33.42%46.38K | -39.96%45.87K | -45.13%284.72K | -46.56%69.34K | -46.57%69.34K | -46.32%69.65K | -41.07%76.39K |
| Asset impairment expenditure | 3.69%806.01K | -110.04%-111.64K | -66.37%98.93K | 4,820.07%1.75M | -56.94%-927.9K | 170.60%777.33K | 157.83%1.11M | 293.35%294.16K | 93.28%-37K | -205.79%-591.25K |
| Unrealized gains and losses of investment securities | -24.13%-3.2M | -156.92%-1.06M | 131.08%1.2M | --362.47K | -536.06%-3.7M | -713.78%-2.58M | 692.15%1.86M | -311,215.89%-3.86M | --0 | -350.02%-581.84K |
| Remuneration paid in stock | --0 | --0 | ---- | ---- | ---- | -46.98%234.89K | --0 | --234.89K | ---- | ---- |
| Deferred tax | --369.49K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other non cashItems | 52.99%-898.46K | -600.46%-180.33K | 64.79%-219.86K | 85.49%-88.56K | 42.48%-409.72K | 33.62%-1.91M | -91.32%36.03K | 21.35%-624.48K | 66.60%-610.3K | -5.90%-712.3K |
| Change In working capital | 268.92%1.38M | 478.52%1.3M | 301.79%149.2K | 183.99%606.53K | 5.33%-682.56K | -420.84%-814.38K | -167.23%-344.09K | 116.09%37.13K | 270.83%213.57K | -45.67%-720.99K |
| -Change in receivables | 10,119.83%751.49K | 484.23%293.43K | --58.86K | 51.03%515.71K | 70.81%-116.51K | -109.38%-7.5K | -74.98%50.23K | --0 | 2,947.81%341.45K | -2,449.35%-399.18K |
| -Change in prepaid assets | 98.33%-16.05K | ---- | ---- | ---- | ---- | ---958.31K | ---- | ---- | ---- | ---- |
| -Change in payables and accrued expense | 322.77%640.2K | 81.76%1.03M | 143.27%90.33K | 171.02%90.82K | -75.89%-566.05K | 164.08%151.43K | 81.28%563.99K | 126.96%37.13K | -283.78%-127.88K | 32.86%-321.81K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 14.49%-2.61M | -62.24%-1.01M | 60.09%-340.2K | 31.11%-70.77K | 19.49%-1.19M | 9.95%-3.06M | 35.33%-625.1K | -37.67%-852.48K | 90.78%-102.72K | -112.63%-1.48M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -344.48%-9.61M | -478.87%-1.11M | -160.00%-2.51M | -1,515.16%-7.32M | 224.49%1.33M | 166.80%3.93M | -87.61%292.8K | 1,558.73%4.19M | -64.51%517.18K | 48.23%-1.07M |
| Net PPE purchase and sale | --0 | --0 | --0 | ---- | ---- | 1,547.01%221.39K | --0 | --0 | ---- | ---- |
| Net intangibles purchas and sale | -1,513.40%-6.21M | ---702.43K | ---1.08M | -1,275.99%-4.2M | -188.93%-230.64K | -69.32%-384.74K | --0 | --0 | -2,000.36%-304.91K | -2,453.30%-79.82K |
| Net investment purchase and sale | -98.00%94.06K | --0 | -215.89%-1.43M | --0 | 362.44%1.53M | 203.95%4.71M | -81.99%760.33K | 4,877.84%1.24M | 192.71%3.3M | 94.12%-582.37K |
| Net other investing changes | -469.29%-3.5M | 12.97%-406.9K | -99.99%242 | -15.91%-3.12M | 107.14%28.79K | -109.84%-615.02K | 71.31%-467.53K | 1,099.10%2.95M | 29.11%-2.69M | -103.37%-403.39K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -344.48%-9.61M | -478.87%-1.11M | -160.00%-2.51M | -1,515.16%-7.32M | 224.49%1.33M | 166.80%3.93M | -87.61%292.8K | 1,558.73%4.19M | 119.45%517.18K | -151.77%-1.07M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 4,667.54%9.14M | 4,359.50%1.97M | 1,775.14%2.58M | 4.74M | -139.97K | -346.31%-200.13K | -46.14K | -289.52%-153.98K | 0 | 0 |
| Net issuance payments of debt | --9.26M | --1.97M | --2.58M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Net common stock issuance | 30.06%-139.97K | --0 | --0 | --0 | ---139.97K | ---200.13K | ---46.14K | ---153.98K | --0 | --0 |
| Proceeds from stock option exercised by employees | --24K | --0 | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 4,667.54%9.14M | 4,359.50%1.97M | 1,775.49%2.58M | --4.74M | ---139.97K | -346.31%-200.13K | ---46.14K | -289.52%-153.98K | --0 | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | 23.19%3.59M | -83.28%663.83K | 51.26%937.37K | 857.58%3.59M | 23.19%3.59M | -38.66%2.92M | 161.12%3.97M | -73.58%619.7K | -81.27%375.03K | -38.66%2.92M |
| Current changes in cash | -556.46%-3.09M | 58.23%-158.08K | -108.16%-273.55K | -1,184.67%-2.65M | 99.94%-1.64K | 136.79%676.31K | -127.12%-378.44K | 506.22%3.35M | -28.73%244.67K | 7.66%-2.54M |
| End cash Position | -85.92%505.74K | -85.92%505.74K | -83.28%663.83K | 51.26%937.37K | 857.58%3.59M | 23.19%3.59M | 23.19%3.59M | 161.12%3.97M | -73.58%619.7K | -81.27%375.03K |
| Free cash from | -149.65%-8.82M | -174.61%-1.72M | -66.44%-1.42M | -915.27%-4.27M | 13.25%-1.42M | 5.24%-3.53M | 47.76%-625.1K | -27.89%-852.48K | 63.65%-420.22K | -130.53%-1.64M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.